1. US Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
2. Medicines and Healthcare Products Regulatory Agency. MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults. 23 Jul 2024. https://www.gov.uk/government/news/mhra-approves-glp-1-receptor-agonist-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults
3. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
4. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
5. UC San Diego Health. Clinical trial studying possible new treatment option for patients with NAFLD. 23 Aug 2023. https://health.ucsd.edu/news/press-releases/2023-08-23-clinical-trial-studying-possible-new-treatment-option-for-patients-with-nafld/